Triple attack on liver cancer: blocking blood flow plus immune boost shows promise
NCT ID NCT07658833
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining procedures that block blood flow to liver tumors (TACE or HAIC) with targeted drugs and immunotherapy can help control advanced hepatocellular carcinoma that cannot be surgically removed. The trial enrolls adults aged 18–80 with large or vein-involved tumors and good liver function. Researchers will measure overall survival, tumor shrinkage, and side effects to find the best combination and identify which patients benefit most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib, sorafenib, apatinib, bevacizumab, pembrolizumab, carfilzomib, sintilimab, teprotumumab
- What this could lead to
- If successful, this combination approach could offer a new way to control advanced liver cancer and extend survival for patients who cannot have surgery.
- What could go wrong
- This is a single-center study with 120 participants, so results may not apply broadly. Combining multiple treatments also raises the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiayan Ni
RECRUITINGGuangzhou, None Selected, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?